1,1-dichloroethene increases expression ISO Map2k5 (Rattus norvegicus) 6480464 vinylidene chloride results in increased expression of MAP2K5 protein CTD PMID:14565772 1,2,4-trimethylbenzene decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 pseudocumene results in decreased expression of MAP2K5 protein CTD PMID:17337753 1,2-dimethylhydrazine increases expression EXP 6480464 1 and 2-Dimethylhydrazine results in increased expression of MAP2K5 mRNA CTD PMID:22206623 17beta-estradiol affects expression ISO MAP2K5 (Homo sapiens) 6480464 Estradiol affects the expression of MAP2K5 mRNA CTD PMID:14699072 and PMID:22574217 17beta-estradiol decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Estradiol results in decreased expression of MAP2K5 mRNA CTD PMID:31614463 17beta-estradiol increases expression ISO MAP2K5 (Homo sapiens) 6480464 Estradiol results in increased expression of MAP2K5 mRNA CTD PMID:23094148 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP2K5 mRNA CTD PMID:19465110 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MAP2K5 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO MAP2K5 (Homo sapiens) 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP2K5 mRNA CTD PMID:21296121 3,4-methylenedioxymethamphetamine increases expression EXP 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of MAP2K5 mRNA CTD PMID:20188158 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MAP2K5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of MAP2K5 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of MAP2K5 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol increases methylation ISO MAP2K5 (Homo sapiens) 6480464 bisphenol S results in increased methylation of MAP2K5 gene CTD PMID:31601247 4-hydroxynon-2-enal decreases expression ISO MAP2K5 (Homo sapiens) 6480464 4-hydroxy-2-nonenal results in decreased expression of MAP2K5 mRNA CTD PMID:12419474 4-hydroxyphenyl retinamide increases expression EXP 6480464 Fenretinide results in increased expression of MAP2K5 mRNA CTD PMID:28973697 5-azacytidine decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Azacitidine results in decreased expression of MAP2K5 mRNA CTD PMID:20823114 acetylsalicylic acid decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Aspirin results in decreased expression of MAP2K5 mRNA CTD PMID:15928584 afimoxifene decreases response to substance ISO MAP2K5 (Homo sapiens) 6480464 MAP2K5 results in decreased susceptibility to afimoxifene CTD PMID:21233418 all-trans-retinoic acid decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Tretinoin results in decreased expression of MAP2K5 mRNA CTD PMID:33167477 ammonium chloride affects expression ISO Map2k5 (Rattus norvegicus) 6480464 Ammonium Chloride affects the expression of MAP2K5 mRNA CTD PMID:16483693 arecoline increases expression ISO Map2k5 (Rattus norvegicus) 6480464 Arecoline results in increased expression of MAP2K5 protein CTD PMID:34999050 aristolochic acid A decreases expression ISO MAP2K5 (Homo sapiens) 6480464 aristolochic acid I results in decreased expression of MAP2K5 mRNA CTD PMID:33212167 arsane affects methylation ISO MAP2K5 (Homo sapiens) 6480464 Arsenic affects the methylation of MAP2K5 gene CTD PMID:25304211 arsenic atom affects methylation ISO MAP2K5 (Homo sapiens) 6480464 Arsenic affects the methylation of MAP2K5 gene CTD PMID:25304211 arsenite(3-) increases expression EXP 6480464 arsenite results in increased expression of MAP2K5 mRNA CTD PMID:18191166 benzo[a]pyrene multiple interactions EXP 6480464 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of MAP2K5 mRNA] CTD PMID:22228805 benzo[a]pyrene affects methylation ISO MAP2K5 (Homo sapiens) 6480464 Benzo(a)pyrene affects the methylation of MAP2K5 intron CTD PMID:30157460 benzo[a]pyrene decreases methylation EXP 6480464 Benzo(a)pyrene results in decreased methylation of MAP2K5 intron CTD PMID:27901495 benzo[a]pyrene decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Benzo(a)pyrene results in decreased expression of MAP2K5 mRNA CTD PMID:20064835 more ... benzo[a]pyrene increases expression EXP 6480464 Benzo(a)pyrene results in increased expression of MAP2K5 mRNA CTD PMID:22228805 beta-naphthoflavone multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of MAP2K5 mRNA CTD PMID:18164116 bis(2-chloroethyl) sulfide affects expression ISO Map2k5 (Rattus norvegicus) 6480464 Mustard Gas affects the expression of MAP2K5 mRNA CTD PMID:15651846 bisphenol A increases methylation ISO MAP2K5 (Homo sapiens) 6480464 bisphenol A results in increased methylation of MAP2K5 gene CTD PMID:22576693 bisphenol A decreases methylation ISO MAP2K5 (Homo sapiens) 6480464 bisphenol A results in decreased methylation of MAP2K5 gene CTD PMID:31601247 bisphenol A increases expression ISO Map2k5 (Rattus norvegicus) 6480464 bisphenol A results in increased expression of MAP2K5 mRNA CTD PMID:30816183 and PMID:32528016 bisphenol A increases methylation ISO Map2k5 (Rattus norvegicus) 6480464 bisphenol A results in increased methylation of MAP2K5 gene CTD PMID:28505145 bisphenol A multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MAP2K5 mRNA CTD PMID:28628672 bisphenol A decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 bisphenol A results in decreased expression of MAP2K5 mRNA CTD PMID:25181051 bisphenol A decreases expression ISO MAP2K5 (Homo sapiens) 6480464 bisphenol A results in decreased expression of MAP2K5 mRNA CTD PMID:22576693 butanal decreases expression ISO MAP2K5 (Homo sapiens) 6480464 butyraldehyde results in decreased expression of MAP2K5 mRNA CTD PMID:26079696 carbamazepine affects expression ISO MAP2K5 (Homo sapiens) 6480464 Carbamazepine affects the expression of MAP2K5 mRNA CTD PMID:24752500 CGP 52608 multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 CGP 52608 promotes the reaction [RORA protein binds to MAP2K5 gene] CTD PMID:28238834 chlorpyrifos increases expression EXP 6480464 Chlorpyrifos results in increased expression of MAP2K5 mRNA CTD PMID:37019170 choline multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of MAP2K5 mRNA CTD PMID:20938992 cis-caffeic acid multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Thapsigargin co-treated with caffeic acid] results in decreased expression of MAP2K5 mRNA CTD PMID:19442820 clofibrate decreases expression EXP 6480464 Clofibrate results in decreased expression of MAP2K5 mRNA CTD PMID:17585979 clozapine decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 Clozapine results in decreased expression of MAP2K5 mRNA CTD PMID:15860345 copper atom multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Chelating Agents binds to Copper] which results in increased expression of MAP2K5 mRNA CTD PMID:30911355 copper(0) multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Chelating Agents binds to Copper] which results in increased expression of MAP2K5 mRNA CTD PMID:30911355 dexamethasone multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MAP2K5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of MAP2K5 mRNA CTD PMID:28628672 diclofenac affects expression ISO MAP2K5 (Homo sapiens) 6480464 Diclofenac affects the expression of MAP2K5 mRNA CTD PMID:24752500 dorsomorphin multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K5 mRNA CTD PMID:27188386 fipronil increases expression ISO Map2k5 (Rattus norvegicus) 6480464 fipronil results in increased expression of MAP2K5 mRNA CTD PMID:23962444 flavonoids increases expression ISO Map2k5 (Rattus norvegicus) 6480464 Flavonoids results in increased expression of MAP2K5 mRNA CTD PMID:18035473 folic acid multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of MAP2K5 mRNA CTD PMID:20938992 folic acid increases expression EXP 6480464 Folic Acid results in increased expression of MAP2K5 mRNA CTD PMID:25629700 formaldehyde affects response to substance ISO MAP2K5 (Homo sapiens) 6480464 MAP2K5 gene affects the susceptibility to Formaldehyde CTD PMID:27008852 genistein multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [Genistein co-treated with Methoxychlor] results in increased expression of MAP2K5 mRNA CTD PMID:21782745 haloperidol decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 Haloperidol results in decreased expression of MAP2K5 mRNA CTD PMID:15860345 hesperidin decreases phosphorylation ISO MAP2K5 (Homo sapiens) 6480464 Hesperidin results in decreased phosphorylation of MAP2K5 protein CTD PMID:34984768 hydrogen peroxide decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Hydrogen Peroxide results in decreased expression of MAP2K5 mRNA CTD PMID:12419474 indometacin multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MAP2K5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of MAP2K5 mRNA CTD PMID:28628672 L-methionine multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of MAP2K5 mRNA CTD PMID:20938992 methamphetamine affects response to substance ISO MAP2K5 (Homo sapiens) 6480464 MAP2K5 gene SNP affects the susceptibility to Methamphetamine CTD PMID:18316681 methoxychlor multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [Genistein co-treated with Methoxychlor] results in increased expression of MAP2K5 mRNA CTD PMID:21782745 methoxychlor increases expression ISO Map2k5 (Rattus norvegicus) 6480464 Methoxychlor results in increased expression of MAP2K5 mRNA CTD PMID:21782745 methylmercury chloride decreases expression ISO MAP2K5 (Homo sapiens) 6480464 methylmercuric chloride results in decreased expression of MAP2K5 mRNA CTD PMID:28001369 methylseleninic acid increases expression ISO MAP2K5 (Homo sapiens) 6480464 methylselenic acid results in increased expression of MAP2K5 mRNA CTD PMID:12517777 N(4)-hydroxycytidine decreases expression EXP 6480464 N(4)-hydroxycytidine results in decreased expression of MAP2K5 mRNA CTD PMID:37748715 N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine decreases expression ISO MAP2K5 (Homo sapiens) 6480464 N more ... CTD PMID:12888634 N-methyl-4-phenylpyridinium decreases expression ISO MAP2K5 (Homo sapiens) 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of MAP2K5 mRNA CTD PMID:25234470 N-nitrosodiethylamine multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of MAP2K5 mRNA CTD PMID:18164116 oxaliplatin multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of MAP2K5 mRNA CTD PMID:25729387 oxytocin multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA] and MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein] CTD PMID:29104011 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of MAP2K5 mRNA CTD PMID:11752693 paracetamol decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 Acetaminophen results in decreased expression of MAP2K5 mRNA CTD PMID:33387578 paracetamol decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Acetaminophen results in decreased expression of MAP2K5 mRNA CTD PMID:22230336 pirinixic acid multiple interactions EXP 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of MAP2K5 mRNA CTD PMID:19710929 platycodin D decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 platycodin D results in decreased expression of MAP2K5 protein modified form CTD PMID:29595072 potassium chromate decreases expression ISO MAP2K5 (Homo sapiens) 6480464 potassium chromate(VI) results in decreased expression of MAP2K5 mRNA CTD PMID:22714537 resveratrol multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 MAP2K5 protein promotes the reaction [resveratrol results in increased expression of KLF2 mRNA] more ... CTD PMID:19815564 rutin multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 Rutin inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP2K5 mRNA] CTD PMID:26062544 SB 431542 multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K5 mRNA CTD PMID:27188386 silicon dioxide decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Silicon Dioxide results in decreased expression of MAP2K5 mRNA CTD PMID:25351596 sodium arsenate decreases expression EXP 6480464 sodium arsenate results in decreased expression of MAP2K5 mRNA CTD PMID:30953684 sodium dichromate decreases expression EXP 6480464 sodium bichromate results in decreased expression of MAP2K5 mRNA CTD PMID:22155349 and PMID:31558096 sodium fluoride decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 Sodium Fluoride results in decreased expression of MAP2K5 mRNA CTD PMID:36736877 sulfates multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Soot co-treated with Sulfates] affects the methylation of MAP2K5 promoter CTD PMID:25395096 tert-butyl hydroperoxide decreases expression ISO MAP2K5 (Homo sapiens) 6480464 tert-Butylhydroperoxide results in decreased expression of MAP2K5 mRNA CTD PMID:12419474 tetrachloromethane increases expression ISO Map2k5 (Rattus norvegicus) 6480464 Carbon Tetrachloride results in increased expression of MAP2K5 mRNA CTD PMID:26062544 tetrachloromethane affects expression ISO Map2k5 (Rattus norvegicus) 6480464 Carbon Tetrachloride affects the expression of MAP2K5 mRNA CTD PMID:17805973 tetrachloromethane multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 Rutin inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP2K5 mRNA] CTD PMID:26062544 thapsigargin multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Thapsigargin co-treated with 4-methoxycinnamate methyl ester] results in decreased expression of MAP2K5 mRNA more ... CTD PMID:19442820 thapsigargin decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Thapsigargin results in decreased expression of MAP2K5 mRNA CTD PMID:19442820 thioacetamide decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 Thioacetamide results in decreased expression of MAP2K5 mRNA CTD PMID:34492290 topotecan multiple interactions ISO Map2k5 (Rattus norvegicus) 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of MAP2K5 mRNA CTD PMID:25729387 trans-caffeic acid multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [Thapsigargin co-treated with caffeic acid] results in decreased expression of MAP2K5 mRNA CTD PMID:19442820 troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of MAP2K5 mRNA CTD PMID:28973697 undecane decreases expression ISO Map2k5 (Rattus norvegicus) 6480464 undecane results in decreased expression of MAP2K5 protein CTD PMID:17337753 urethane increases expression ISO MAP2K5 (Homo sapiens) 6480464 Urethane results in increased expression of MAP2K5 mRNA CTD PMID:28818685 valproic acid decreases expression ISO MAP2K5 (Homo sapiens) 6480464 Valproic Acid results in decreased expression of MAP2K5 mRNA CTD PMID:23179753 and PMID:26272509 valproic acid multiple interactions ISO MAP2K5 (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K5 mRNA CTD PMID:27188386
